Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. Source
No articles found.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
Although intended for the lungs, many drugs are not given via the airway because d...
Although intended for the lungs, many drugs are...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Chembio is a leading point-of-care diagnostics company focused on detecting and di...
Chembio is a leading point-of-care diagnostics ...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietar...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, ...
Landec Corporation (Nasdaq: LNDC) is a leading innovator of diversified health and...
Landec Corporation (Nasdaq: LNDC) is a leading ...
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing nov...
Idera Pharmaceuticals is a clinical-stage bioph...
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...
iCAD, Inc. an industry-leading provider of adva...
Join the National Investor Network and get the latest information with your interests in mind.